Quercus Robur Pollen

Dosage for Quercus Robur Pollen is highly individualized and must be titrated based on the patient's sensitivity levels. There is no 'standard' dose for all patients.

Diagnostic Dosing

• Skin Prick Test (SPT): Usually performed using a 1:10 or 1:20 w/v glycerinated extract. A single drop is applied to the skin, and the skin is pricked through the drop.
• Intradermal Test: If the SPT is negative but suspicion remains high, a 1:1000 or 1:100 w/v aqueous extract may be injected (0.02 mL) to create a small bleb.

Therapeutic Dosing (Immunotherapy)

• Build-up Phase: Treatment typically starts with a very dilute solution (e.g., 1:100,000 w/v). Injections are given 1–2 times per week, with the dose increasing by 25–50% each time, provided the patient tolerates the previous dose without a significant local or systemic reaction.
• Maintenance Phase: Once the 'top dose' or maximum tolerated dose is reached (often 1:10 or 1:20 w/v), the interval between injections is increased to every 2–4 weeks. Maintenance therapy usually continues for 3 to 5 years.

Quercus Robur Pollen is generally considered safe for use in children, though it is rarely initiated in children under the age of 5 due to the difficulty of monitoring for systemic reactions and the child's ability to cooperate with the injection schedule. Dosing for children follows the same weight/volume titration principles as adult dosing, though the physician may choose a more conservative escalation schedule.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the extract is not cleared through the kidneys in a manner that affects its primary mechanism or toxicity.

Hepatic Impairment

No dosage adjustments are necessary for hepatic impairment.

Elderly Patients

Elderly patients should be evaluated for cardiovascular stability before beginning immunotherapy. The dose itself is not adjusted based on age, but the risk-benefit ratio must be carefully considered, particularly if the patient is on medications like beta-blockers.

Quercus Robur Pollen extract is strictly for professional use and is never self-administered by the patient at home.

• Administration: It is injected subcutaneously (just under the skin), usually in the posterior aspect of the upper arm.
• Observation: Patients MUST remain in the medical office for at least 30 minutes following every injection to be monitored for signs of anaphylaxis.
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). They should never be frozen, as this can denature the allergenic proteins.

If a dose is missed during the build-up phase, the next dose may need to be reduced depending on how much time has passed.

• 1–2 weeks late: Repeat the last dose.
• 3–4 weeks late: Reduce the dose by one or two increments.
• Over 4 weeks late: The physician may need to restart the build-up from a much lower concentration to ensure safety.

An overdose of Quercus Robur Pollen (either giving too much volume or a concentration that is too high) can lead to severe systemic reactions, including anaphylactic shock.

• Signs: Rapid onset of hives, swelling of the throat, wheezing, low blood pressure, and loss of consciousness.
• Emergency Measures: Immediate administration of epinephrine (1:1000) intramuscularly, followed by oxygen, IV fluids, and antihistamines. Emergency medical services must be contacted immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip appointments without medical guidance.

Most patients undergoing immunotherapy with Quercus Robur Pollen will experience some form of local reaction. These are generally not dangerous but can be uncomfortable.

• Local Redness (Erythema): Redness at the site of injection, usually appearing within minutes and lasting a few hours.
• Local Swelling (Wheal): A raised, warm bump at the injection site. If the swelling is smaller than the size of a half-dollar (approx. 3 cm), it is considered a normal response.
• Itching (Pruritus): Intense itching at the injection site is common and can be managed with topical hydrocortisone or oral antihistamines.

• Large Local Reactions (LLR): Swelling that exceeds 5–10 cm in diameter. These may peak 6–12 hours after the injection and persist for 24–48 hours.
• Fatigue: Some patients report feeling unusually tired for several hours after their allergy shot.
• Mild Nasal Congestion: A slight 'flare' of hay fever symptoms shortly after administration.

• Generalized Urticaria (Hives): Hives appearing on parts of the body far from the injection site.
• Angioedema: Swelling of the lips, eyelids, or extremities.
• Vasovagal Syncope: Fainting or lightheadedness due to the needle stick or anxiety, rather than the extract itself.

> Warning: Stop taking Quercus Robur Pollen and call your doctor immediately if you experience any of these.

• Anaphylaxis: This is a life-threatening systemic allergic reaction. Symptoms include a 'sense of impending doom,' swelling of the tongue, difficulty swallowing, and a rapid drop in blood pressure.
• Bronchospasm: Sudden wheezing, chest tightness, or shortness of breath. This is more common in patients with pre-existing asthma.
• Laryngeal Edema: Swelling in the throat that makes it difficult to breathe or speak.
• Hypotension: Dizziness or fainting caused by a sudden decrease in blood pressure.

There are no known long-term adverse effects associated with the proper use of Quercus Robur Pollen extract. Decades of clinical use have shown that allergen immunotherapy does not increase the risk of autoimmune diseases, malignancy, or chronic organ damage. In fact, long-term use is associated with a 'disease-modifying' effect, potentially preventing the development of asthma in children with allergic rhinitis.

Allergenic extracts, including Quercus Robur Pollen, carry an FDA-mandated warning regarding the risk of severe systemic reactions.

• Summary: This product can cause life-threatening anaphylaxis. It must only be administered in a setting where emergency equipment and trained personnel are available to treat such reactions. Patients with unstable asthma are at a significantly higher risk for fatal reactions and should be evaluated carefully before each dose.

Report any unusual symptoms to your healthcare provider.

Quercus Robur Pollen is a potent biological product. Safety depends on accurate skin testing, appropriate dose titration, and strict adherence to administration protocols. Patients must be healthy at the time of injection; if you have a fever, respiratory infection, or an active asthma flare-up, your injection should be postponed.

No FDA black box warnings for Quercus Robur Pollen are listed in the same format as oral pharmaceuticals, but the Standardized Warning for Allergenic Extracts is functionally equivalent. It states that the extract may cause severe, life-threatening systemic reactions. It must be administered by physicians who are exceptionally familiar with the product and equipped to treat anaphylaxis. Patients must be observed for 30 minutes post-injection.

• Anaphylaxis Risk: Every injection carries a small but real risk of a systemic reaction. Patients should be educated on how to recognize the early signs of anaphylaxis.
• Asthma Status: Patients with uncontrolled or severe asthma (FEV1 < 70% of predicted) are at the highest risk for severe or fatal reactions to immunotherapy. Asthma must be well-controlled before an injection is given.
• Beta-Blocker Use: Patients taking beta-blockers (used for heart conditions or migraines) may be resistant to the effects of epinephrine, the primary treatment for anaphylaxis. This makes any allergic reaction significantly more dangerous.

No routine lab tests (like liver or kidney function) are required for Quercus Robur Pollen. However, clinical monitoring is intensive:

• Pre-Injection Assessment: The clinician will check for current allergy symptoms, asthma stability, and the size of the previous injection's local reaction.
• Post-Injection Observation: A 30-minute mandatory wait time in the clinic is standard practice.
• Peak Flow Monitoring: For asthmatic patients, a peak flow meter may be used to ensure lung function is stable before and after the injection.

Quercus Robur Pollen does not typically cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine for a reaction, they should not drive or operate machinery until they have fully recovered and been cleared by a medical professional.

Alcohol should be avoided for several hours before and after an injection. Alcohol causes vasodilation (widening of blood vessels), which can increase the speed of allergen absorption and potentially increase the risk or severity of a systemic reaction.

Immunotherapy is typically discontinued after 3–5 years of successful maintenance. There is no 'withdrawal syndrome' associated with stopping Quercus Robur Pollen. However, stopping prematurely (before 3 years) significantly increases the risk that allergy symptoms will return quickly.

> Important: Discuss all your medical conditions with your healthcare provider before starting Quercus Robur Pollen.

• Beta-Adrenergic Blockers: Drugs like propranolol, atenolol, or metoprolol are generally contraindicated or used with extreme caution. The clinical consequence is that if the patient has an anaphylactic reaction to the oak pollen extract, the beta-blocker will prevent epinephrine from working effectively, potentially leading to a fatal outcome.

• ACE Inhibitors: Some studies suggest that patients taking ACE inhibitors (e.g., lisinopril) may have a higher risk of more severe systemic reactions to immunotherapy, possibly due to interference with the breakdown of kinins.
• MAO Inhibitors (MAOIs): Drugs like phenelzine can potentiate the effect of epinephrine, which could complicate the treatment of an allergic reaction.

• Other Allergen Immunotherapy: If a patient is receiving multiple types of allergy shots (e.g., oak, grass, and dust mites), the cumulative 'allergic load' may increase the risk of a systemic reaction. Doses may need to be adjusted if multiple injections are given on the same day.
• Tricyclic Antidepressants: Similar to MAOIs, these can increase the cardiovascular response to epinephrine used in emergencies.

• Alcohol: As mentioned, alcohol can increase the rate of allergen absorption and should be avoided on injection days.
• Heavy Meals: Very large, hot meals immediately after an injection can increase core body temperature and blood flow, potentially affecting the absorption of the extract.

• Feverfew or Butterbur: While these are used for allergies, they have not been studied for interactions with Quercus Robur Pollen.
• St. John's Wort: May affect the metabolism of other medications used to treat allergic reactions, though direct interaction with the pollen extract is unlikely.

• Skin Tests: Quercus Robur Pollen will interfere with subsequent skin tests for other allergens if the patient is currently in the maintenance phase of immunotherapy (due to the production of blocking antibodies).
• Specific IgE (n-CAP/RAST): Immunotherapy can cause a temporary rise in specific IgE levels before they eventually decline over years of treatment.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Severe, Uncontrolled Asthma: Patients with a forced expiratory volume in 1 second (FEV1) of less than 70% of predicted or those with frequent exacerbations must not receive Quercus Robur Pollen immunotherapy. The risk of a fatal bronchospasm is too high.
• Recent Myocardial Infarction (Heart Attack): Patients with unstable angina or recent heart attacks should not undergo immunotherapy because they cannot tolerate the cardiovascular stress of a systemic reaction or the epinephrine required to treat it.
• Hypersensitivity to Excipients: Patients with a known severe allergy to glycerin or phenol (preservatives used in the extract) must not use these products.

• Beta-Blocker Therapy: While not an absolute contraindication in all guidelines, many allergists will not perform immunotherapy on patients taking these medications due to the risk of epinephrine-resistant anaphylaxis.
• Autoimmune Disorders: Patients with active, systemic autoimmune diseases (like SLE or Rheumatoid Arthritis) are often excluded from immunotherapy, although this is a case-by-case decision.
• Malignancy: Immunotherapy is generally not started in patients with active cancer.

Patients allergic to Quercus Robur Pollen may show cross-sensitivity to other members of the Fagaceae family, including:

• Fagus (Beech)
• Castanea (Chestnut)
• Other Quercus species (White Oak, Red Oak)

This means a skin test for English Oak may also trigger a reaction in a patient primarily allergic to Beech trees.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Quercus Robur Pollen.

Quercus Robur Pollen is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women.

• Initiation: Immunotherapy should not be started during pregnancy due to the risk of anaphylaxis, which can cause fetal hypoxia (lack of oxygen to the baby).
• Maintenance: If a woman is already on a stable maintenance dose and becomes pregnant, the treatment may be continued, as the risk of a reaction is much lower than during the build-up phase. However, the dose is typically not increased during pregnancy.

It is not known whether the components of Quercus Robur Pollen extract are excreted in human milk. Because the extract consists of naturally occurring proteins that are degraded into amino acids, it is generally considered safe to continue maintenance immunotherapy while breastfeeding. No adverse effects have been reported in nursing infants.

Safety and effectiveness have been established in children. However, as noted previously, it is rarely recommended for children under 5 years of age. For older children, it is highly effective in preventing the 'allergic march'—the progression from hay fever to asthma.

Clinical studies of Quercus Robur Pollen did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects. The primary concern in the elderly is the presence of comorbid cardiovascular disease, which increases the risk of complications if a systemic reaction occurs.

No dosage adjustments are required. The proteins in the extract are not known to be nephrotoxic, and their clearance is not dependent on renal function in a way that would increase systemic toxicity.

No adjustments are necessary. The liver is not the primary site of action or degradation for these allergenic proteins.

> Important: Special populations require individualized medical assessment.

Quercus Robur Pollen extract acts as an immunomodulator. In diagnostic use, it triggers a Type I hypersensitivity reaction via IgE-mediated mast cell degranulation. In therapeutic use, it induces peripheral T-cell tolerance. This is achieved through the induction of regulatory T-cells (Tregs) that produce IL-10, which suppresses the Th2 response and induces B-cells to switch from IgE production to IgG4 production. IgG4 acts as a 'blocking antibody,' preventing the allergen from reaching the IgE bound to mast cells.

• Onset of Action: For skin testing, the onset is 15–20 minutes. For immunotherapy, clinical improvement typically takes 6–12 months of consistent treatment.
• Duration of Effect: The diagnostic effect lasts as long as the patient remains sensitized. The therapeutic effect of a full 3–5 year course can last for years or even decades after treatment is stopped.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous) |

| Protein Binding | N/A |

| Half-life | Hours (Local degradation) |

| Tmax | 15-30 minutes (Local peak) |

| Metabolism | Proteolytic enzymes |

| Excretion | Renal (Metabolites only) |

Quercus Robur Pollen extract is a complex mixture of proteins, glycoproteins, and polysaccharides. The primary allergens are often proteins in the 10–70 kDa range. The extract is typically standardized by Protein Nitrogen Units (PNU) or weight of the raw pollen per volume of extracting fluid (w/v).

Quercus Robur Pollen is a Non-Standardized Pollen Allergenic Extract. It is grouped with other tree pollen extracts such as Birch, Hickory, and Maple extracts.